Industry
Medical - Devices
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Loading...
Open
3.44
Mkt cap
362M
Volume
775
High
3.45
P/E Ratio
-10.09
52-wk high
5.54
Low
3.43
Div yield
N/A
52-wk low
3.23
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 9:24 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 8:44 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 12:09 pm
Portfolio Pulse from Avi Kapoor
March 20, 2024 | 12:20 pm
Portfolio Pulse from Avi Kapoor
March 20, 2024 | 9:32 am
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 4:02 pm
Portfolio Pulse from Avi Kapoor
March 13, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 11:03 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.